Since the introduction of 18F-FDG in 1976 (1)(Figs. 1–2), the last 3 decades have witnessed
a revolution in medical imaging. The widespread use of 18F-FDG PET as a molecular probe …

The rationale was to develop recommendations on the use of 18F-FDG PET in breast,
colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma …

Early detection of recurrence is clinically important and can improve the prognosis and
survival of patients with cancer. CT, considered the primary method of investigation because …

Advances in technology have allowed extremely precise control of radiation dose delivery
and localization within a patient. The ability to confidently delineate target tumor boundaries …

[18F] FDG has been the first radiopharmaceutical used for human brain PET studies and still
is the most used radiotracer worldwide for PET and PET/CT oncologic applications. In the …

Objective The aim of this study was to systematically review the literature to evaluate the
clinical performance of integrated 18 F-FDG PET/MR as compared with 18 F-FDG PET/CT in …

In the last decade there have been important advances in the potentially curative treatment
of locoregionally advanced solid tumors with radiotherapy. The increasing trend toward …

For over 40 years, 18F-FDG has been the dominant PET tracer in neurology, cardiology,
inflammatory diseases, and, most particularly, oncology. Combined with the ability to …

The intention of this review is to provide information about the rapidly evolving field of
molecular imaging and its potential impact on the clinical practice of nuclear medicine. On …

Positron emission tomography (PET) has become a very useful adjunct to anatomic imaging
techniques, adding unique information to the characterization of disease. The whole-body …